Myovant: FDA Extends Review Of Myfembree In Pain Associated

Myovant: FDA Extends Review Of Myfembree In Pain Associated With Endometriosis To August 6

NEW YORK CITY (dpa-AFX) - The U.S. Food and Drug Administration has extended the review period for the supplemental New Drug Application or sNDA for Myfembree for the management of moderate to

Related Keywords

, Pfizer Inc , Myovant Sciences , Drug Administration , New Drug Application , Prescription Drug User Fee Act , Myovant , Xtends , Review , Myfembree , Rain , Ssociated , Ith , Endometriosis , August ,

© 2025 Vimarsana